Theravance Biopharma Inc TBPH:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:03 PM EDT
9.60UNCH (UNCH)
Volume
25,999
Close
9.60quote price arrow down-0.25 (-2.54%)
Volume
355,071
52 week range
8.21 - 11.71
Loading...
  • Open9.71
  • Day High9.74
  • Day Low9.37
  • Prev Close9.85
  • 52 Week High11.71
  • 52 Week High Date01/04/24
  • 52 Week Low8.21
  • 52 Week Low Date02/08/24

Key Stats

  • Market Cap466.176M
  • Shares Out48.56M
  • 10 Day Average Volume0.34M
  • Dividend-
  • Dividend Yield-
  • Beta0.28
  • YTD % Change-12.37

KEY STATS

  • Open9.71
  • Day High9.74
  • Day Low9.37
  • Prev Close9.85
  • 52 Week High11.71
  • 52 Week High Date01/04/24
  • 52 Week Low8.21
  • 52 Week Low Date02/08/24
  • Market Cap466.176M
  • Shares Out48.56M
  • 10 Day Average Volume0.34M
  • Dividend-
  • Dividend Yield-
  • Beta0.28
  • YTD % Change-12.37

RATIOS/PROFITABILITY

  • EPS (TTM)-0.86
  • P/E (TTM)-11.15
  • Fwd P/E (NTM)-14.33
  • EBITDA (TTM)-39.785M
  • ROE (TTM)-15.56%
  • Revenue (TTM)61.51M
  • Gross Margin (TTM)31.69%
  • Net Margin (TTM)-72.78%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/05/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Theravance Biopharma Inc

 

Profile

MORE
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps...
Rick Winningham
Chairman of the Board, Chief Executive Officer
Aziz Sawaf
Chief Financial Officer, Senior Vice President
Address
UGLAND HOUSE, SOUTH CHURCH STREET
George Town
KY1-1104
Cayman Islands

Top Peers

SYMBOLLASTCHG%CHG
EDIT
Editas Medicine Inc
5.89-0.11-1.83%
ADCT
ADC Therapeutics SA
4.09-0.04-0.97%
URGN
Urogen Pharma Ltd
13.21-0.57-4.14%
YMAB
Y-mAbs Therapeutics Inc
11.85-0.33-2.71%
ALEC
Alector Inc
5.49-0.16-2.83%